Low-Dose CD7 CAR-T Cell Therapy Shows 93.5% Response Rate in Relapsed T-Cell Lymphomas

A groundbreaking phase I clinical trial has demonstrated that low-dose CD7 (搜索)搜索该靶点 chimeric antigen receptor T-cell therapy achieves exceptional response rates in patients with relapsed or refractory T-cell lymphomas (搜索)搜索该疾病, offering new hope for a patient population with historically poor outcomes. The study, conducted between August 2022 and April 2024, enrolled 40 patients and represents a significant advancement in CAR-T cell therapy dosing strategies.

Remarkable Efficacy at Reduced Doses

The trial achieved an overall response rate of 92.5% across all dose levels, with the phase Ib cohort of 31 patients demonstrating a 93.5% overall response rate and an 80.6% complete response rate. Most notably, these results were achieved using a median dose of 1×10⁵ CAR-T cells per kilogram of body weight—tenfold lower than previously reported effective doses.

The patient population included predominantly T-lymphoblastic lymphoma (搜索)搜索该疾病 cases (87.5%, n=35), with the remainder having rare mature T-cell lymphoma subtypes. Patients had received a median of 3 prior therapies, and 55% had previously undergone hematopoietic stem cell transplantation, indicating a heavily pretreated, high-risk population.

IntraBlock Technology Enables Dose Reduction

The study utilized CD7 CAR-T cells (搜索)搜索该药品 manufactured with IntraBlock technology, which prevents fratricide—the self-destruction of CAR-T cells that naturally express the CD7 (搜索)搜索该靶点 target antigen. This technological advancement allowed for the dramatic dose reduction while maintaining therapeutic efficacy. All 40 patients successfully met dosage requirements for infusion after a 7-day manufacturing period, with no manufacturing failures reported.

The reduced dosing strategy has important clinical implications, as it reduces manufacturing burden, lowers costs, and expands access to patients with limited autologous T-cell availability who would otherwise be ineligible for conventional CAR-T cell therapy.

Safety Profile and Toxicity Management

Despite the lower doses, hematologic toxicity remained nearly universal, with 97.5% of patients experiencing grade ≥3 neutropenia (搜索)搜索该疾病 and 85% experiencing grade ≥3 thrombocytopenia (搜索)搜索该疾病. However, recovery was faster than typically observed with higher-dose regimens. Among patients with severe neutropenia, 56.4% recovered to grade 2 within one month, while 38.2% of those with severe thrombocytopenia reached grade 2 within the same timeframe.

Cytokine release syndrome (搜索)搜索该疾病 occurred in 92.5% of patients, with only 2 grade 3 cases requiring tocilizumab查看药品详情 and corticosteroids. The median onset was 1 day with a median duration of 7 days. Immune effector cell-associated neurotoxicity syndrome (搜索)搜索该疾病 occurred in only two patients, including one grade 4 case that resolved after intensive care management.

Infections occurred in 30% of patients within 30 days, consisting of bacterial (50%), viral (41.7%), and fungal (8.3%) infections, all of which were successfully treated. Beyond one month post-infusion, infections occurred in 26 patients, with seven deaths from infection-related complications.

Survival Outcomes and Transplant Benefits

During a median 30-month follow-up, the median progression-free survival and overall survival among responders were 7.05 months and 16.34 months, respectively. The two-year progression-free survival and overall survival rates were 40.1% and 36.9%, respectively.

A critical finding was the significant survival benefit observed in patients who received consolidative allogeneic stem cell transplantation after CAR-T-induced remission. These 16 patients had a significantly better 2-year overall survival rate of 54.1% compared to 23.1% in the 13 patients who did not undergo transplantation (P = 0.038). The transplant group also showed a trend toward better 2-year progression-free survival (54.1% vs 23.1%, P = 0.063).

Antigen Escape and Resistance Mechanisms

Among the 37 responders, 29.7% experienced relapse during follow-up. Analysis of tumor surface antigens in the 11 relapsed patients revealed concerning patterns of antigen escape: 4 remained CD7 (搜索)搜索该靶点-positive, 2 exhibited low CD7 expression, and 5 experienced CD7-negative relapse. The high rate of CD7-negative relapse (72.7%) exceeded that reported in previous studies, suggesting antigen escape via CD7 downregulation or loss as a dominant resistance mechanism.

CAR-T Cell Expansion and Persistence

CD7 CAR-T cells (搜索)搜索该药品 demonstrated robust expansion, with a median peak at 14 days post-infusion and a median peripheral count of 82.1×10⁶/L. The CAR transgene remained detectable by PCR up to day 396, indicating durable persistence. Notably, seven of ten patients with CNS involvement had detectable CAR gene copies in cerebrospinal fluid, demonstrating the therapy's ability to penetrate sanctuary sites.

Clinical Implications and Future Directions

The study's heterogeneous patient population, encompassing both early-stage T-lymphoblastic lymphoma (搜索)搜索该疾病 and aggressive mature T-cell lymphomas (搜索)搜索该疾病 with high tumor burden, CNS involvement, or prior transplant failure, demonstrates the broad applicability of this approach. The therapy achieved high remission rates at extramedullary and CNS disease sites (90.6% and 100%, respectively), overcoming microenvironmental resistance mechanisms.

The researchers noted that future strategies should explore dual-targeting CAR-T cell designs, such as CD7 (搜索)搜索该靶点/CD5 or CD7/CD1a combinations, or combination approaches with epigenetic modulators to reduce lineage plasticity and clonal evolution. The emerging "all-in-one" strategy—sequential CAR-T cell therapy followed by haploidentical stem cell transplantation without GVHD prophylaxis—may improve outcomes by preserving immune reconstitution while leveraging graft-versus-lymphoma effects.